Back to top
more

Tarsus Pharmaceuticals (TARS)

(Real Time Quote from BATS)

$47.15 USD

47.15
603,062

+5.51 (13.23%)

Updated Aug 7, 2025 11:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 10.20% and 30.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 102.47% and 1,450.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -9.86% and 71.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 63.08% and 8.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of -12.64% and 90.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.